---
schema_version: "secwatch.filing_event.v1"
accession: "0001213900-25-059753"
form_type: "8-K"
ticker: "GRML"
cik: "0001907223"
company_name: "Greenland Mines Ltd"
filed_at: "2025-06-30T23:59:59+00:00"
generated_at: "2026-05-18T14:49:01.179916+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Klotho Neurosciences begins manufacturing of ALS gene therapy KLTO-202, targeting Phase I/II start by Q3 2026

## Summary
- KLTO-202 gene therapy manufacturing underway; process development & manufacturing expected to take approx. 8 months.
- Company targets FDA meetings, animal safety studies, IND filing, and Phase I/II trial start by Q3 2026.
- Therapy uses s-KL RNA splice variant of alpha-Klotho gene licensed from Autonomous University of Barcelona.
- Animal studies in ALS, Alzheimer's, and aging models showed favorable therapeutic outcomes.
- Company will use CROs to manage manufacturing and clinical trials, avoiding large staff increases.

## SEC filing metadata
- accession: 0001213900-25-059753
- form_type: 8-K
- ticker: GRML
- cik: 0001907223
- company_name: Greenland Mines Ltd
- filed_at: 2025-06-30T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1907223/000121390025059753/0001213900-25-059753-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1907223/000121390025059753/ea0247557-8k_klotho.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001213900-25-059753
- JSON: https://secwatch.observer/filing/0001213900-25-059753.json
- Plain text: https://secwatch.observer/filing/0001213900-25-059753.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.